Tirzepatide Research for Obesity
An evidence-based overview of research examining Tirzepatide in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Tirzepatide received FDA approval for chronic obesity management in 2023 (as Zepbound). The SURMOUNT clinical program demonstrated consistent, substantial weight reduction across various populations. In SURMOUNT-1, 91% of participants on the 15mg dose achieved clinically meaningful weight loss (5% or more), with 57% achieving 20% or greater reduction. SURMOUNT-5 directly compared tirzepatide with semaglutide in adults with obesity or overweight without diabetes and found greater mean weight loss with tirzepatide at 72 weeks. SURMOUNT-MMO is evaluating morbidity and mortality in a different population. Its registration is not an outcome result and cannot yet establish the same cardiovascular effect observed in SELECT.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.